---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-062194"
form_type: "8-K"
ticker: "JSPR"
cik: "0001788028"
company_name: "Jasper Therapeutics, Inc."
filed_at: "2025-07-09T23:59:59+00:00"
generated_at: "2026-05-18T08:54:39.676946+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Jasper Therapeutics cuts workforce ~50%, halts non-urticaria programs; CMO departs

## Summary
- Workforce reduction of ~50% and halting of all non-chronic urticaria programs.
- Estimated $1.8M-$2.2M in severance cash expenditures through Q3 2025.
- CMO Edwin Tucker departs effective Aug 1, 2025; receives 12 months base salary and COBRA.
- Dr. Daniel Adelman appointed Acting Chief Medical Officer effective Aug 1, 2025.
- Focus on briquilimab in CSU/CIndU; data from BEACON/SPOTLIGHT expected later this year.

## SEC filing metadata
- accession: 0001213900-25-062194
- form_type: 8-K
- ticker: JSPR
- cik: 0001788028
- company_name: Jasper Therapeutics, Inc.
- filed_at: 2025-07-09T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.05, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1788028/000121390025062194/0001213900-25-062194-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1788028/000121390025062194/ea0248394-8k_jasper.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-062194
- JSON: https://secwatch.observer/filing/0001213900-25-062194.json
- Plain text: https://secwatch.observer/filing/0001213900-25-062194.txt

## Key facts
- Restructurings & Charges
  Jasper Therapeutics, Inc. announced a restructuring with charges of approximately $1.8 million - $2.2 million affecting the Company (approximately 50%).
  - Type: restructuring
  - Charge: approximately $1.8 million - $2.2 million
  - Affected area: the Company
  - Headcount: approximately 50%
  source text: in chronic urticaria and is halting other clinical and preclinical programs along with the reduction in workforce. The Company estimates that it will incur approximately $1.8 million - $2.2 million of cash expenditures in connection with the corporate reorganization, which relate to severance pay, and are expected to be incurred through the quarter ending
  evidence_url: https://www.sec.gov/Archives/edgar/data/1788028/000121390025062194/0001213900-25-062194-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.